{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:08:09Z","timestamp":1758935289587},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.clim.2011.01.010","type":"journal-article","created":{"date-parts":[[2011,1,26]],"date-time":"2011-01-26T04:21:34Z","timestamp":1296015694000},"page":"155-163","source":"Crossref","is-referenced-by-count":9,"title":["Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses"],"prefix":"10.1016","volume":"139","author":[{"given":"Matthaios","family":"Speletas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikoletta","family":"Argentou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaios","family":"Karanikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia S.","family":"Gramoustianou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eudokia","family":"Mandala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Braimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiota","family":"Matsouka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Ritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios E.","family":"Germenis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2011.01.010_bb0005","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.01.010_bb0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.leukres.2004.06.012","article-title":"CML cytogenetic relapse after cessation of imatinib therapy","volume":"29","author":"Usuki","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.clim.2011.01.010_bb0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2011.01.010_bb0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","article-title":"K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clim.2011.01.010_bb0025","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0145-2126(00)00065-5","article-title":"Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies","volume":"24","author":"Shinozawa","year":"2000","journal-title":"Leuk Res"},{"key":"10.1016\/j.clim.2011.01.010_bb0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2004.10.034","article-title":"Survivin expression in chronic myeloid leukemia","volume":"225","author":"Contea","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clim.2011.01.010_bb0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/10428190500052131","article-title":"Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients","volume":"46","author":"Hernandez-Boluda","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clim.2011.01.010_bb0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0037-1963(03)70046-8","article-title":"Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia","volume":"40","author":"Schwartz","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clim.2011.01.010_bb0045","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.clim.2011.01.010_bb0050","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/25141","article-title":"Control of apoptosis and mitotic spindle checkpoint by survivin","volume":"396","author":"Li","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.clim.2011.01.010_bb0055","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood.V97.9.2784","article-title":"Cytokine-regulated expression of survivin in myeloid leukemia","volume":"97","author":"Carter","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.01.010_bb0060","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/1078-0432.CCR-03-0642","article-title":"High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia","volume":"10","author":"Creutzig","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clim.2011.01.010_bb0065","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.1158\/0008-5472.CAN-05-0303","article-title":"Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis","volume":"65","author":"Wang","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clim.2011.01.010_bb0070","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","article-title":"Regulation of survivin expression through Bcr-Abl\/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells","volume":"107","author":"Carter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.01.010_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2006.12.020","article-title":"Survivin: a promising tumor biomarker","volume":"249","author":"Duffy","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clim.2011.01.010_bb0080","first-page":"6097","article-title":"Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties","volume":"59","author":"Mahotka","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.clim.2011.01.010_bb0085","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.bbrc.2003.12.178","article-title":"Identification of a novel splice variant of the human anti-apoptosis gene survivin","volume":"314","author":"Badran","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clim.2011.01.010_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-4598-4-11","article-title":"Survivin 2a: a novel survivin splice variant expressed in human malignancies","volume":"4","author":"Caldas","year":"2005","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clim.2011.01.010_bb0095","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1038\/sj.onc.1208038","article-title":"An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy","volume":"23","author":"Zhu","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.clim.2011.01.010_bb0100","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clim.2011.01.010_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/cbt.7.3.5424","article-title":"Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy","volume":"7","author":"Karanikas","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clim.2011.01.010_bb0110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDCT) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.clim.2011.01.010_bb0115","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.clim.2011.01.010_bb0120","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1200\/JCO.2005.05.3314","article-title":"Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma","volume":"24","author":"Coughlin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clim.2011.01.010_bb0125","first-page":"5964","article-title":"Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients","volume":"61","author":"Andersen","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.clim.2011.01.010_bb0130","first-page":"1731","article-title":"An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin","volume":"8","author":"Hirohashi","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clim.2011.01.010_bb0135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clim.2008.07.024","article-title":"Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals","volume":"129","author":"Karanikas","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clim.2011.01.010_bb0140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"Response definitions and European Leukemianet Management recommendations","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clim.2011.01.010_bb0145","first-page":"589","article-title":"Expression of the antiapoptotic gene survivin in chronic myeloid leukemia","volume":"23","author":"Badran","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clim.2011.01.010_bb0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ijc.10450","article-title":"Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas","volume":"100","author":"Mahotka","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clim.2011.01.010_bb0155","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjc.6600153","article-title":"Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumor progression","volume":"86","author":"Krieg","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clim.2011.01.010_bb0160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.lungcan.2005.03.037","article-title":"Differential expression of survivin-2B and survivin-Dex3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer","volume":"49","author":"Ling","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clim.2011.01.010_bb0165","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00018-002-8518-3","article-title":"Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer","volume":"59","author":"Zaffaroni","year":"2002","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clim.2011.01.010_bb0170","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10549-005-9153-0","article-title":"High survivin predicts a poor response to endocrine therapy but a good response to chemotherapy in advanced breast cancer","volume":"98","author":"Span","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clim.2011.01.010_bb0175","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/jnci\/93.20.1541","article-title":"Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy","volume":"93","author":"Kanwar","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clim.2011.01.010_bb0180","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2011.01.010_bb0185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/hupa.2001.21897","article-title":"Expression of survivin in normal, hyperplastic and neoplastic colonic tissue","volume":"42","author":"Gianani","year":"2001","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clim.2011.01.010_bb0190","doi-asserted-by":"crossref","first-page":"11480","DOI":"10.1073\/pnas.0500303102","article-title":"Differential requirements for survivin in hematopoietic cell development","volume":"102","author":"Gurbuxani","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clim.2011.01.010_bb0195","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1084\/jem.20031588","article-title":"Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis","volume":"199","author":"Xing","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.clim.2011.01.010_bb0200","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood.V98.7.2091","article-title":"Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis","volume":"98","author":"Fukuda","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clim.2011.01.010_bb0205","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0002-9440(10)64131-4","article-title":"Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting","volume":"158","author":"Mesri","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clim.2011.01.010_bb0210","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1535-7163.MCT-05-0375","article-title":"Survivin, a cancer target with an emerging role in normal adult tissues","volume":"5","author":"Fukuda","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clim.2011.01.010_bb0215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2009.03.015","article-title":"Anti-survivin antibody responses in lung cancer","volume":"281","author":"Karanikas","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clim.2011.01.010_bb0220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00002371-200307000-00008","article-title":"Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery","volume":"26","author":"Tanaka","year":"2003","journal-title":"J Immunother"},{"key":"10.1016\/j.clim.2011.01.010_bb0225","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1084\/jem.20081382","article-title":"Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response","volume":"206","author":"Rizzuto","year":"2009","journal-title":"J Exp Med"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661611000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661611000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T03:26:51Z","timestamp":1543980411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661611000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1521661611000295"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2011.01.010","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}